Global News

Sanford-Burnham, Pfizer collaborate

Thursday, August 15, 2013 11:14 AM

Sanford-Burnham Medical Research Institute has signed a three-year collaboration agreement with Pfizer to identify therapeutic targets for preventing and treating complications of obesity and diabetes. The team will utilize novel screening tools including systems-biology approaches and technologies developed at Sanford-Burnham with the aim of discovering therapeutic strategies for reducing insulin resistance in obesity and diabetes.

More... »

Amgen, Servier complete product collaboration

Thursday, August 15, 2013 09:30 AM

Biotechnology company Amgen and privately-run French research-based pharmaceutical company Servier have announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement announced  July 8, completing the transaction.

More... »

Quintiles to acquire Novella Clinical

Wednesday, August 14, 2013 01:22 PM

CRO Quintileshas signed an agreement to acquire Novella Clinical, a full-service CRO focused primarily on emerging oncology customers as well as those in the medical device and diagnostics sectors. 

More... »

China’s type 2 diabetes market forecast to grow to $3.5 billion by 2017

Wednesday, August 14, 2013 01:20 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, forecasts the type 2 diabetes therapeutic market in China, the third largest after the U.S. and Japan, will grow 10% annually, reaching $3.5 billion in 2017. Fueling this expansion are the growing number of drug-treated patients and the increasing use of dipeptidyl peptidase-4 (DPP-IV) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and insulin analogues.

More... »

Pharmstandard seeks to acquire Bever Pharmaceutical

Wednesday, August 14, 2013 01:15 PM

Pharmstandard has announced key terms for a possible acquisition of 100% of the share capital of Bever Pharmaceutical. It is expected that Bever will be included in a proposed spin-off of the company's branded over-the-counter business.

More... »

MRC Technology, Parkinson's U.K. launch joint call for targets

Wednesday, August 14, 2013 01:12 PM

MRC Technology, a technology transfer organization, and Parkinson's U.K., a support and research charity, have announced a joint call for targets. The call aims to identify and fund either one or two projects focused on potential small molecule or antibody targets to slow, stop or reverse the progression of Parkinson's. The call to academic researchers seeks to fund target validation and proof-of-concept studies prior to initiating a full-scale drug discovery project.

More... »

Study Scavenger, CenterWatch partner to widen reach

Wednesday, August 14, 2013 01:07 PM

Study Scavenger, the first bilingual smartphone app to allow patients to search for clinical research studies that meet their health, travel and financial needs, and CenterWatch are partnering to provide sponsors, CROs, research centers and patients a mobile solution to clinical trial needs. 

More... »

BBK Worldwide wins silver and bronze Web Health Awards

Tuesday, August 13, 2013 12:21 PM

Patient recruitment company BBK Worldwide has been awarded two Web Health Awards for excellence in the Mobile Application Resource and e-Business categories. The company received a Silver Web Health Award in the mobile application resource category for its patient engagement mobile app, Health Info Gizmo. BBK also received a Bronze Web Health Award in the e-business category for its e-commerce site, shop.BBKWorldwide.com. The Web Health Awards recognize high-quality digital health resources for consumers and health professionals.

More... »

PPD names David Johnston executive vice president

Tuesday, August 13, 2013 11:30 AM

CRO Pharmaceutical Product Development (PPD) has appointed David Johnston, Ph.D., executive vice president of global laboratory services. Johnston directs PPD’s comprehensive laboratory services, including bioanalytical, vaccines and biologics, current good manufacturing practice (cGMP) and central laboratories.

More... »

Torrey Pines Investment, BioMotiv partner for drug development investments

Tuesday, August 13, 2013 10:30 AM

San Diego, Calif.-based Torrey Pines Investment (TPI), a specialty life-science investor, and BioMotiv, an accelerator company associated with The Harrington Project for Discovery & Development, have signed a joint investment framework to fund early stage life-science programs and companies over the next seven years. 

More... »